Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Clopidogrel matches aspirin for reducing risk of colorectal cancer

Publish date:: July 30, 2019

Key clinical point: Clopidogrel usage appears to reduce the risk of colorectal cancer as much as low-dose aspirin.

Major finding: Current clopidogrel usage was associated with a 20% reduced risk of colorectal cancer (adjusted odds ratio, 0.8).

Study details: A nested case-control study involving 15,491 cases of colorectal cancer and 60,000 controls.

Disclosures: The study was funded by the Fundación Instituto Teóﬁlo Hernando. Dr. García-Rodríguez disclosed a relationship with CEIFE, which has received funding from Bayer and AstraZeneca.

Citation:

Rodríguez-Miguel A et al. Clin Gastrenterol Hepatol. 2018 Dec 20. doi: 10.1016/j.cgh.2018.12.012.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Annual WCC visits significantly limit asthma worsening,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Microplastics permeate human placentas,

Must Reads in Gastroenterology

Younger adults present with more advanced esophageal adenocarcinoma,

Anorexia and diarrhea top list of GI symptoms in COVID-19 patients,

IBD patients prefer vedolizumab over anti-TNF drugs,

During pandemic, many gastroenterologists report low resilience, insomnia,

Upper GI bleeds in COVID-19 not related to increased mortality,